PDCD1 and head and neck squamous cell carcinoma: PD-1 inhibitors, specifically nivolumab and pembrolizumab, have been sanctioned for treating recurrent/metastatic HNSCC, showcasing extended OS in contrast to chemotherapy (44–46).